Barely Significant
← all excerpts

Oblimersen for the treatment of patients with chronic lymphocytic leukemia.

Ther Clin Risk Manag · 2007 · PMC2376092 · PMID 18473009

Europe PMC
1
hedged sentence
0.0020
closest p · 0.0× alpha
0.0020
boldest claim

The sentences

difference was apparentP = 0.002actually significant
highly significantP = 0.002actually significant
Moreover, based on an intent-to-treat analysis of response duration, a highly significant difference was apparent that favored the oblimersen plus Flu/Cy group (hazard ratio = 0.62; P = 0.002; see Figure 4 .

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.